Be the first person to write a business review for Trubion Pharmaceuticals, Inc.

U.S. Genomics, Inc. company has developed the GeneEngine, a DNA sequencer that mimics natural cell division, rapidly reading and copying DNA. It is developing the technology to quickly detect and identify infectious pathogens and biomarkers for biodefense and diagnostic use. Its products can detect and quantify molecules of DNA, RNA, and proteins without amplification. Backed by private equity investors and biomedical firms including Becton Dickinson, U.S. Genomics has netted contracts with the Department of Homeland Security. Northrup Gruman is the company's bio-security development partner.

Urigen Pharmaceuticals, Inc. (Urigen) is a specialty pharmaceutical company engaged in the development and commercialization of therapeutic products for urological disorders. The Company’s product pipeline includes URG101, for the treatment of Painful Bladder Syndrome (PBS), which has completed a Phase II double blinded, placebo controlled, multi-center trial, and URG301, targeting urethritis and nocturia. Urigen specializes in the development of products for patients with urological ailments including, specifically, the development of products for amelioration Painful Bladder Syndrome/Interstitial Cystitis (PBS or PBS/IC), Urethritis, Nocturia and Overactive Bladder (OAB). Urology represents a specialty pharmaceutical market of approximately 12,000 physicians in North America. Urologists treat a variety of ailments of the urinary tract including urinary tract infections, bladder cancer, overactive bladder, urgency and incontinence and interstitial cystitis, a subset of PBS.

Vanda Pharmaceuticals was founded in 2002 and is headquartered in Rockville, Maryland. Vanda Pharmaceuticals Inc., a biopharmaceutical company, engages in the development and commercialization of clinical-stage drug candidates for central nervous system disorders. Its product portfolio includes Iloperidone (oral), a compound for the treatment of schizophrenia completed Phase III clinical trial; and Tasimelteon, which completed Phase III clinical trials for transient insomnia and chronic primary insomnia. The company's products also comprise Iloperidone (Injectible) for the treatment of schizophrenia and Tasimelteon for the treatment of depression, which are in the Phase II initiation status.

Vaxon Biotech is a biopharmaceutical company focused on the treatment of cancers and related malignancies. Disease targets include breast, lung, pancreatic, and prostate cancer. The company's claim to fame is its development of optimized cryptic peptide antigens (substances that trigger protein responses in the immune system), which have shown early progress in the immune response against these cancers. The company's development products are classified as therapeutic vaccines and are developed to trigger the immune system to attack malignant cells in solid tumors while steering clear from normal cells.

Vernalis plc company was founded in 1986 and is based in Winnersh, the United Kingdom. Vernalis plc, a development stage pharmaceutical company, engages in de novo structure and fragment-based drug discovery, and pre-clinical and clinical development primarily in Europe and North America. It primarily involves in the research, development, and commercialization of pharmaceutical products for a range of medical disorders. The company’s products include Frovatriptan, a 5-HT1B/1D receptor agonist, which is approved as an acute oral treatment for migraine headache and its associated symptoms; and Apokyn, an acute intermittent therapy for the treatment of re-emergence of Parkinson’s disease symptoms associated with advanced Parkinson’s disease. Its product pipeline comprises V3381/Indantadol, a Phase IIb study novel small molecule with a dual mechanism for the treatment of neuropathic pain; V85546, a Phase I study selective MMP 12 inhibitor for inflammation; V1512/Levodopa methyl ester/carbidopa, a Phase II trial product for Parkinson’s disease treatment; V2006, an adenosine A2A receptor antagonist in Phase IIa study for the treatment of Parkinson’s disease; NVP-AUY922, a novel Hsp90 inhibitor, which is in Phase I program for the treatment of a range of cancers, including solid tumors and hematological cancers; V158866 Fatty Acid Amide Hydrolase, a pre-clinical stage product for pain management; V10153, a Phase IIa recombinant human thrombolytic protein for the treatment of acute ischemic stroke; and V24343, a Phase I study cannabinoid type 1 receptor antagonist for the treatment of obesity, diabetes, and related disorders.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.